Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
34
MGNX Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-11.43%
Day range:
$1.47 - $1.58
52-week range:
$0.99 - $5.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.63x
P/B ratio:
1.21x
Volume:
796K
Avg. volume:
2M
1-year change:
-71.77%
Market cap:
$95.9M
Revenue:
$148.3M
EPS (TTM):
-$0.89
Analysts' Opinion
-
Consensus RatingMacrogenics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.20, Macrogenics has an estimated upside of 176.32% from its current price of $1.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.52.
Fair Value
-
According to the consensus of 6 analysts, Macrogenics has 176.32% upside to fair value with a price target of $4.20 per share.
MGNX vs. S&P 500
-
Over the past 5 trading days, Macrogenics has underperformed the S&P 500 by -4.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Macrogenics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Macrogenics has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Macrogenics reported revenues of $13.2M.
Earnings Growth
-
Macrogenics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Macrogenics reported earnings per share of -$0.65.
Enterprise value:
-58.2M
EV / Invested capital:
--
Price / LTM sales:
0.63x
EV / EBIT:
--
EV / Revenue:
-0.38x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.80x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$136.8M
Return On Assets:
-23.25%
Net Income Margin (TTM):
-36.62%
Return On Equity:
-58.23%
Return On Invested Capital:
-58.23%
Operating Margin:
-323.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $163.4M | $41.8M | $152.4M | $9.1M | $13.2M | |
| Gross Profit | $152.6M | $35M | $136.8M | $7M | $7.8M | |
| Operating Income | -$93.2M | -$183.6M | -$99.5M | -$53.8M | -$42.6M | |
| EBITDA | -$78.7M | -$12.8M | -$47.3M | -$49.2M | -$39.2M | |
| Diluted EPS | -$1.47 | -$0.39 | -$0.89 | -$0.84 | -$0.65 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $374.7M | $218.2M | $288.9M | $202.6M | $182.1M | |
| Total Assets | $435.4M | $271.4M | $343.5M | $248.3M | $224.6M | |
| Current Liabilities | $53M | $67.1M | $45.6M | $55.8M | $55.4M | |
| Total Liabilities | $84.9M | $93.2M | $234.2M | $142.1M | $145.4M | |
| Total Equity | $350.5M | $178.2M | $109.3M | $106.2M | $79.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.1M | -$111M | -$69.6M | -$45.6M | -$46.9M | |
| Cash From Investing | $117.3M | -$83.4M | $134.4M | $24.8M | $9.9M | |
| Cash From Financing | $101.7M | $50.5M | $430K | $248K | -$282K | |
| Free Cash Flow | -$44.7M | -$113.9M | -$72.4M | -$47.1M | -$47.4M | |
MGNX
Sector
Market Cap
$95.9M
$34.4M
Price % of 52-Week High
26.34%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-71.77%
-37.36%
Beta (5-Year)
1.587
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.53
200-day SMA
Sell
Level
$2.52
Bollinger Bands (100)
Sell
Level
1.23 - 2.07
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Buy
Level
$1.40
Relative Strength Index (RSI14)
Buy
Level
53.22
ADX Line
Buy
Level
25.05
Williams %R
Neutral
Level
-27.957
50-day SMA
Buy
Level
$1.48
MACD (12, 26)
Buy
Level
0.42
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.9262)
Sell
CA Score
(Annual)
Level (-1.3955)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.5348)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Stock Forecast FAQ
In the current month, MGNX has received 1 Buy ratings 5 Hold ratings, and 0 Sell ratings. The MGNX average analyst price target in the past 3 months is $4.20.
-
Where Will Macrogenics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Macrogenics share price will rise to $4.20 per share over the next 12 months.
-
What Do Analysts Say About Macrogenics?
Analysts are divided on their view about Macrogenics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Macrogenics is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Macrogenics's Price Target?
The price target for Macrogenics over the next 1-year time period is forecast to be $4.20 according to 6 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is MGNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Macrogenics is a Hold. 5 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MGNX?
You can purchase shares of Macrogenics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Macrogenics shares.
-
What Is The Macrogenics Share Price Today?
Macrogenics was last trading at $1.55 per share. This represents the most recent stock quote for Macrogenics. Yesterday, Macrogenics closed at $1.52 per share.
-
How To Buy Macrogenics Stock Online?
In order to purchase Macrogenics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
